Table 2.
Management of anticoagulant therapy and 3-month outcomes in patients with micro pulmonary thrombo-embolism (mPE) and central PE (cPE).
| All | cPE | mPE | p Value | |
|---|---|---|---|---|
| LMWH (as starting anticoagulant therapy) | 56 (100%) | 31 (100%) | 25 (100%) | n.s. |
| Switch from LMWH to oral anticoagulant therapy | 46 (82%) | 29 (94%) | 17 (68%) | 0.001 |
| LMWH duration before switch (days from PE diagnosis) | 16 ± 8 | 16 ± 9 | 15 ± 6 | n.s. |
| Vitamin K antagonist n (%) | 7 (15%) | 4 (14%) | 3 (18%) | n.s. |
| INR in patients on VKA, median (IQR) | 2.3 (1.9–2.7) | 2.4 (2.1–2.9) | 2.3 (1.9–2.7) | n.s. |
| DOAC n (%) | 39 (85%) | 25 (86%) | 14 (82%) | n.s. |
| 30-day follow-up | n.s. | |||
| Exitus | 4 | 2 | 2 | |
| Recurrence of PE | 0 | 0 | 0 | |
| Bleedings (minor/major) | 0 | 0 | 0 | |
| 3-month follow-up | n.s. | |||
| Exitus | 0 | 0 | 0 | |
| Recurrence of PE | 0 | 0 | 0 | |
| Bleedings (minor/major) | 0 | 0 | 0 | |
| Length of hospitalization (days) | 28 ± 16 | 30 ± 18 | 25 ± 11 | n.s. |
LMWH = Low-molecular-weight heparin; OAC = Oral Anticoagulant; DOAC = direct oral anticoagulant; VKA = Vitamin K antagonist; n.s.: not significant.